|
Vitamin D for Healthy Kidney Transplants
dailyRx The study showed that vitamin D levels were directly related to how well patients’ kidneys filtered waste out of the blood in the years after transplant surgery. Patients with lower levels of vitamin D were more likely to have an organ rejection. The … |
Crash victim's elbow saved in pioneering transplant surgery – Evening Standard
Evening Standard |
Crash victim’s elbow saved in pioneering transplant surgery
Evening Standard A mother of two who suffered severe arm injuries in a car crash has undergone pioneering transplant surgery. Jo Macleod’s shattered right elbow was rebuilt by surgeons using tissue from a donor. Doctors re-sculpted the bone then grafted a donor tendon … |
Weekend Things To Do in the South Bay, Harbor Area – Daily Breeze
|
Weekend Things To Do in the South Bay, Harbor Area
Daily Breeze Ben Hur — A Tale of the Christ: 1926 silent film with some color sequences and live accompaniment; show includes music played on the pipe organ, an audience sing along, a comedy short and a 15-minute intermission, followed by the feature film. 8:15 p … |
Teenage organ donor honoured for saving lives – Torquay Herald Express
Torquay Herald Express |
Teenage organ donor honoured for saving lives
Torquay Herald Express The new award for the families and loved ones of those who saved and improved people’s lives through organ donation has been created by the Order of St John alongside NHS Blood and Transplant.”My son was a very popular boy who was very much a … |
LEAKED: 'The Bachelorette India' Winner Is Vijay Singh – Business of Cinema
Business of Cinema |
LEAKED: ‘The Bachelorette India‘ Winner Is Vijay Singh
Business of Cinema Week after week Mallika Sherawat eliminated the suitors, leaving only Karan Sagoo and Vijay Singh to finally make a place in Mallika’s heart. One could see that Mallika was fond of Karan from the word go, but Vijay slow and steadily reached on the top. Mallika Sherawat and I are made for each other, says The Bachelorette winner …Daily News & Analysis Vijay Singh too young for marriage, says familyYahoo India News |
Peregrine's Bavituximab in Combination With Anti-CTLA-4 Antibodies Yields … – Benzinga
|
Peregrine’s Bavituximab in Combination With Anti-CTLA-4 Antibodies Yields …
Benzinga Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced the presentation of data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland being held November 7-10. The data showed that phosphatidylserine … Data Presentation at Society for Immunotherapy of Cancer Annual Meeting …MENAFN.COM |
Gilead Sciences, Inc. : Gilead Announces Phase 2 Results for Sofosbuvir-Based … – 4-traders (press release)
Gilead Sciences, Inc. : Gilead Announces Phase 2 Results for Sofosbuvir-Based …4-traders (press release)In a second study conducted among post-transplant HCV patients (Study 0126), patients with established recurrent HCV infection following liver tra…
Top News From ACR 2013: Slideshow – Medscape
MedscapeTop News From ACR 2013: SlideshowMedscapeRituximab (Rituxan, Genentech) is a potential treatment option in immunoglobulin G4-related disease (IgG4), say researchers reporting first evidence. Lead investigator John Stone, MD, from Massachusetts …
OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) – Opportunity … – PR Carbon (press release)
|
OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) – Opportunity …
PR Carbon (press release) FOR IMMEDIATE RELEASE, Illinois – United States – November 8, 2013 (PR Carbon):Reportstack has announced a new market report on OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) – Opportunity Analysis and Forecasts to 2017. |
Pfizer Inc. : Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of … – 4-traders (press release)
Drug Discovery & Development |
Pfizer Inc. : Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of …
4-traders (press release) Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant. The primary … Pfizer Inc. (NYSE:PFE) | Pfizer Announces Top-Line Results Of Phase 3B/4 …Jutia Group Pfizer says organ transplant drug fails in studyBusinessweek Pfizer’s Rapamune Doesn’t Meet Primary Endpoint in Study of Kidney Transplant …Wall Street Journal |